Phibro Animal Health Q4 2022 Financial Results Earnings

Phibro Animal Health reported fourth quarter and full-year FY2022 earnings with 11-18% year-over-year net sales growth across its animal health, mineral nutrition, and performance products segments. The company provided FY2023 guidance of $960 million to $1 billion in net sales and adjusted EBITDA of $113-118 million, despite facing supply chain headwinds and elevated input costs. A gene therapy collaboration for canine mitral valve disease was announced for 2023 development.